10 E 102nd StNew York, NY 10029
Fax+1 212-241-3908
Overview of Dr. Jagannath
Dr. Sundar Jagannath is a New York-based oncologist specializing in hematologic oncology. He completed his medical education at Baroda Medical College in 1976 followed by several residencies in internal medicine. Dr. Jagannath has significant experience in hematologic oncology, bone marrow transplantation, and multiple myeloma. He has contributed to various publications on multiple myeloma, including studies on treatment patterns and outcomes. Additionally, he has been involved in clinical trials focusing on treatment advancements in multiple myeloma. Dr. Jagannath has been recognized with honors such as the Top Doctors award from Castle Connolly and Super Doctor from SuperDoctors.com.
Education & Training
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1980 - 1982
Wayne State University School of MedicineResidency, Internal Medicine, 1979 - 1980
BronxCare Health SystemResidency, Internal Medicine, 1977 - 1979
Baroda Medical CollegeClass of 1976
Certifications & Licensure
FL State Medical License 2017 - 2027
NJ State Medical License 2017 - 2027
NY State Medical License 1998 - 2027
CT State Medical License 2025 - 2026
MI State Medical License 1979 - 2020
TX State Medical License 1980 - 2011
AR State Medical License 1989 - 2000
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014
- Top Doctors: New York Metro Area Castle Connolly, 2002-2014
- New York Magazine: Top Doctors Castle Connolly, 2004, 2013
Clinical Trials
Publications & Presentations
PubMed
- Health-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1.James E Hoffman, Naresh Bumma, Joshua Richter, Madhav V Dhodapkar, Hans C Lee
Blood Neoplasia. 2026-08-01 - Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma.Mickael Tordjman, Anis Meribout, Amine Geahchan, Ian Bolger, Murat Yuce
American Journal of Hematology. 2026-08-01 - Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.Joshua Richter, Hans C Lee, Sundar Jagannath, Jeffrey A Zonder, James E Hoffman
Leukemia & Lymphoma. 2026-07-10
Abstracts/Posters
- A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple MyelomaSundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) TherapySundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Authored Content
- Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients with Relapsed or Refractory Multiple MyelomaJune 2016
Press Mentions
Long-Term Remission After Cilta-Cel in Patients with RRMMNovember 13th, 2025
Lynozyfic Approved for Relapsed/Refractory Multiple MyelomaJuly 7th, 2025
With Lynozyfic Approval, Regeneron Takes on J&j’s Tecvayli and Talvey, and Pfizer’s Elrexfio in Bispecific Myeloma SpaceJuly 4th, 2025
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPOHIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:











